BMRN PE Ratio & Valuation, Is BMRN Overvalued

Historical Valuation

BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.45 is considered Undervalued compared with the five-year average of 38.52. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 68.73 to 243.93 according to relative valuation method. Compared to the current price of 60.32 USD , BioMarin Pharmaceutical Inc By Undervalued By 12.24%.

Relative Value

Fair Zone

68.73-243.93

Current Price：60.32

12.24%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BioMarin Pharmaceutical Inc (BMRN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BioMarin Pharmaceutical Inc (BMRN) has a current Price-to-Book (P/B) ratio of 1.89. Compared to its 3-year average P/B ratio of 2.79, the current P/B ratio is approximately -32.40% higher. Relative to its 5-year average P/B ratio of 3.14, the current P/B ratio is about -39.92% higher. BioMarin Pharmaceutical Inc (BMRN) has a Forward Free Cash Flow (FCF) yield of approximately 7.29%. Compared to its 3-year average FCF yield of 2.56%, the current FCF yield is approximately 185.00% lower. Relative to its 5-year average FCF yield of 1.78%, the current FCF yield is about 309.78% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BMRN competitors is 40.47, providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN.O) exhibits a P/S ratio of 3.39, which is -91.62% above the industry average. Given its robust revenue growth of 17.03%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BMRN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BMRN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BMRN currently overvalued or undervalued?

BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.45 is considered Undervalued compared with the five-year average of 38.52. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 68.73 to 243.93 according to relative valuation method. Compared to the current price of 60.32 USD, BioMarin Pharmaceutical Inc is Undervalued By 12.24%.

What is BioMarin Pharmaceutical Inc (BMRN) fair value?

BMRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 68.73 to 243.93 according to relative valuation method.

How does BMRN's valuation metrics compare to the industry average?

The average P/S ratio for BMRN's competitors is 40.47, providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN) exhibits a P/S ratio of 3.39, which is -91.62% above the industry average. Given its robust revenue growth of 17.03%, this premium appears unsustainable.

What is the current P/B ratio for BioMarin Pharmaceutical Inc (BMRN) as of Mar 12 2026?

As of Mar 12 2026, BioMarin Pharmaceutical Inc (BMRN) has a P/B ratio of 1.89. This indicates that the market values BMRN at 1.89 times its book value.

What is the current FCF Yield for BioMarin Pharmaceutical Inc (BMRN) as of Mar 12 2026?

As of Mar 12 2026, BioMarin Pharmaceutical Inc (BMRN) has a FCF Yield of 7.29%. This means that for every dollar of BioMarin Pharmaceutical Inc's market capitalization, the company generates 7.29 cents in free cash flow.

What is the current Forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN) as of Mar 12 2026?

As of Mar 12 2026, BioMarin Pharmaceutical Inc (BMRN) has a Forward P/E ratio of 13.45. This means the market is willing to pay $13.45 for every dollar of BioMarin Pharmaceutical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BioMarin Pharmaceutical Inc (BMRN) as of Mar 12 2026?

As of Mar 12 2026, BioMarin Pharmaceutical Inc (BMRN) has a Forward P/S ratio of 3.39. This means the market is valuing BMRN at $3.39 for every dollar of expected revenue over the next 12 months.

BMRN Valuation